MR VACCINES MARKET ANALYSIS

The measles and rubella (MR) vaccine, which protects against measles and rubella, is recommended by the Centers for Disease Control and Prevention (CDC). MR vaccine should be given to children in two doses, the first at 12 to 15 months of age and the second at 4 to 6 years of age. Measles is a highly contagious virus that continues to be one of the leading vaccine-preventable causes of childhood death. High fever and severe skin rash are among the symptoms of measles. Rubella is a virus-borne infectious disease. Rubella causes a mild sickness in most people, with symptoms such as a low-grade fever, sore throat, and a rash that begins on the face and spreads to the rest of the body. The majority of people who are vaccinated against measles and rubella (MR) will be protected for the rest of their lives. Vaccines and high immunization rates have made these diseases much less common in the U.S.

The MR vaccines market is estimated to be valued at US$ 5 million in 2021 and is expected to exhibit a CAGR of 2.1% over the forecast period (2021-2028).

Figure 1. MR Vaccines Market Share (%), By Region, 2021

To learn more about this report, request sample copy

The increase in ongoing clinical trials is expected to drive growth of the MR vaccines market over the forecast period.

For instance, in November 2019, PT Bio Farma, an Indonesian state-owned enterprise, completed a Phase II / III clinical trial of Measles-Rubella (MR) vaccine. The study aimed to evaluate safety and immunogenicity of MR vaccine in Indonesian infants from 9 to 12 months of age.

Figure 2. MR Vaccines Market Share (%), By Distribution Channel, 2021

To learn more about this report, request sample copy

The increasing government initiatives to launch vaccine campaigns is expected to drive the market growth over the forecast period.

For instance, in January 2020, the Ministry of Health and Family Welfare (MOHFW) launched Measles and Rubella vaccination campaign with support from UNICEF and World Health Organization (WHO). An objective of this campaign was to reach all children with age group 6 months to children less than 10 years at the Rohingya refugee camps of stateless Indo-Aryan people.

MR Vaccines Market– Impact of Coronavirus (Covid-19) Pandemic

The COVID-19 pandemic and lockdown in various countries across the globe have negatively impacted the financial status of businesses across all sectors. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry mainly due to strict lockdown in several regions. While the COVID-19 measures such as social distancing, masks, and hand hygiene also minimized the spread of the measles virus.

For instance, according to the data published by World Health Organization (WHO), in November 2021, more than 22 million infants missed their first dose of measles vaccine throughout 2020 and more than 3 million in 2019. This resulted in a hike in measles incidence. In addition, 24 measles vaccination campaigns planned for 2020 in 23 countries, were postponed due to COVID-19 pandemic which left more than 93 million people at risk for the disease. Such campaigns are required for people who have missed out on measles-rubella vaccines. The COVID-19 pandemic made significant disruptions to immunization services and changes in health-seeking nature in many parts across the globe.

MR Vaccines Market Restraint

The risk of adverse reactions associated with measles and rubella (MR) vaccines are expected to hinder the growth of the MR vaccines market over the forecast period.

For instance, according to a report published by the U.S. National Library of Medicine in January 2021, adverse reactions related to Measles and Rubella vaccination are fever, followed by vomiting, abdominal pain, and dizziness. After 4-5 days of MR vaccine administration, few children may have abnormal body movements. In few cases, altered sensorium was detected on the same day as vaccine delivery.

Key Players

Major players operating in the MR vaccines market include PT Bio Farma, Bio-Manguinhos, BE Vaccines, Serum Institute of India, and Crucell Switzerland AG.